Dr. Dan Stickler
speaker
120 appearances
1 recordings
1 series
first heard Nov 2024
last heard Nov 2024
Dr. Dan Stickler’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Oh, yeah. I mean, and before you have to be careful because you don't want to pre-frame people either.
i mean you can create an experience for them by the way you do it and a lot of these the shamans that are out there that they became shamans because of their success with the psychedelic that they're promoting they tend to take people on their journey rather than take people on their own journey and so pre-framing can be kind of problematic you also have to
You know, kind of find out because I've seen this happen where people can wake up and experience emptiness in a session and their psyche is not ready to experience emptiness in true existential crisis there. It's a powerful tool.
Yeah, so I've done a deep dive into MDMA and I'm excited for what's happening with it right now. I mean, you're right. I mean, 500,000 therapy sessions prior to 1984 when it was classified as a scheduled drug. And the therapists and researchers at the time were outraged. They're like, you can't take this away. This has been so successful with our treatments, with what we're seeing in the research.
up through the executive courts. And they won the appeals, but the DEA refused to overturn their decision. And the DEA has that right, which was not the best way to do it. Hoping RFK has some new say in this. But yeah, I mean, it is a super effective drug and we're at a crossroads right now because medicalizing it has some drawbacks to it. legalizing it has some drawbacks to it.
So what route are we going to go with this? I mean, we saw, you know, look at medicalization when it comes to like ketamine. It prompted all these ketamine clinics to come up all over the country and they've been effective, but they could have been more effective had they been set up in the right way.
I mean, we know with psychedelics set and setting is like a huge part of the effect you're going to get. And walking into a sterile looking clinic, having an IV put in your arm and you're laying there on the table and somebody comes by and checks your vital signs periodically. Is not a setting I want to be in.
With MDMA therapy, I mean, it's like all these rules, you know, don't touch the person. I mean, if somebody's taken MDMA and they have to lay there and not be touched, you know, but you also have to have that. The legal aspects of that.
I mean, it's such a tricky area right now. But it is a medication that is, I mean, you saw the results of the MAPS study. And I'm not sure what the FDA committee was thinking.
The FDA committee said they couldn't believe that there was this lack of side effects with it. They couldn't believe that it was this effective overall. I mean, it was just like it met the perfect outcome and they just refused to believe that that was possible without some kind of manipulation of the data.
The Tuesday blues day.
Yeah, that's been pretty much debunked by a lot of the researchers because prior to allowing it in research, the researchers had to rely on recreational users to get their data. Okay. And a lot of it was this occurs because people are using MDMA out partying and They're drinking with it. They're taking other drugs with it. They're not eating, not hydrating or overhydrating.
And because they're partying with it, they don't sleep well the night before or the day after. And that's the perfect formula for having the symptoms of the neurotransmitter deficit.
And when they actually looked at people who did it the right way with just sticking with the one drug, eating while they're taking it, which is hard to do because it's an appetite suppressant, but making themselves eat something and getting a good night's sleep especially that people didn't have to take supplements or anything like that, that they were just fine.
Yeah, we had a female executive. She was with a Fortune 500 company. And she was noticing that her edge was dropping off. She was around, I think, 52 years old. She had started losing her hormones, but she wasn't really being symptomatic. So her doctor said, you know, we're not going to put you on hormones if you're
you're not having any symptoms, that's going to increase your risk of breast cancer. and all of this. And this is one of the failures of evidence-based medicine. Evidence-based medicine has been valuable, but it's also reductionistic. And you can't treat a human in a reductionistic way because we're a complex adaptive system.
And the Women's Health Initiative truly set women's health back for the last 20 years by taking hormones away from women. And it resulted in there's going to be increase in dementia rates, quality of life just deteriorated over those 20 years that women were denied the hormones.
This was based on evidence-based medicine of the Women's Health Initiative and the sensational headlines that it created. Physicians were all buying into evidence-based medicine. That was the new medicine, you know, have the evidence of it. But it's reductionistic in the fact that it groups everybody into the population. And, you know, we saw this happen with the Women's Health Initiative.
We saw this happen with the low-fat craze of the 80s and 90s where everything was healthy as long as it didn't have fat. I mean, you know, sugar corn pops got the heart healthy label on it because it didn't have fat in it. And that resulted in a lot of metabolic disorders and cardiovascular disease because of that. But that was our evidence-based medicine approach.
The statin issues, even the opioid epidemic where pain became that symptom that had to be addressed and treated. rather than looking at individuals from an N of 1 basis. I mean, you can use the evidence-based medicine to guide what you look at with the individual, but you've got to look at the individual there.
Showing 41–60 of 120 · page 3 of 6
← Previous
Next →